ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s share price shot up 5.2% on Friday . The company traded as high as $2.59 and last traded at $2.45. 1,617,271 shares traded hands during mid-day trading, a decline of 1% from the average session volume of 1,628,559 shares. The stock had previously closed at $2.33.
A number of research firms have recently weighed in on ZIOP. Zacks Investment Research lowered shares of ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. BidaskClub lowered shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, December 22nd. HC Wainwright set a $6.00 price objective on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a research report on Tuesday, November 13th. Finally, Raymond James raised shares of ZIOPHARM Oncology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Thursday, November 15th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $4.92.
The firm has a market cap of $321.78 million, a PE ratio of -4.62 and a beta of 2.39.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Friday, November 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, sell-side analysts predict that ZIOPHARM Oncology Inc. will post -0.51 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new stake in ZIOPHARM Oncology in the third quarter valued at approximately $115,000. Jane Street Group LLC purchased a new stake in ZIOPHARM Oncology in the third quarter valued at approximately $161,000. Raymond James & Associates grew its holdings in ZIOPHARM Oncology by 168.3% in the second quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 36,568 shares during the period. MetLife Investment Advisors LLC grew its holdings in ZIOPHARM Oncology by 77.1% in the second quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock valued at $199,000 after purchasing an additional 28,734 shares during the period. Finally, Belpointe Asset Management LLC purchased a new stake in ZIOPHARM Oncology in the third quarter valued at approximately $262,000. Hedge funds and other institutional investors own 40.07% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Zolmax and is the property of of Zolmax. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://zolmax.com/investing/ziopharm-oncology-ziop-shares-up-5-2/2819576.html.
About ZIOPHARM Oncology (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.